Reference
Fogliatto L, et al. Obinutuzumab for CLL relapsed and refractory patients when new oral drugs an not available. Blood 130: 2017. Available from: URL: http://www.bloodjournal.org/content/130/Suppl_1/5341?sso-checked=true [abstract] - Brazil
Rights and permissions
About this article
Cite this article
Chlorambucil/obinutuzumab. Reactions Weekly 1695, 102 (2018). https://doi.org/10.1007/s40278-018-43929-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-018-43929-0